Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb-Mar;32(2):169-80.
doi: 10.1097/CJI.0b013e318194a6e8.

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

Daniel Hollyman  1 , Jolanta Stefanski, Mark Przybylowski, Shirley Bartido, Oriana Borquez-Ojeda, Clare Taylor, Raymond Yeh, Vanessa Capacio, Malgorzata Olszewska, James Hosey, Michel Sadelain, Renier J Brentjens, Isabelle Rivière
Affiliations

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

Daniel Hollyman et al. J Immunother. 2009 Feb-Mar.

Abstract

On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models, we are launching phase I clinical trials in patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia. We present here the validation of the bioprocess which we developed for the production and expansion of clinical grade autologous T cells derived from patients with CLL. We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine leukemia virus encoding a chimeric antigen receptor (CAR) targeted to CD19 (1928z) can be expanded with Dynabeads CD3/CD28. This bioprocess allows us to generate clinical doses of 1928z+ T cells in approximately 2 to 3 weeks in a large-scale semiclosed culture system using the Wave Bioreactor. These 1928z+ T cells remain biologically functional not only in vitro but also in severe combined immunodeficient-beige mice bearing disseminated tumors. The validation requirements in terms of T-cell expansion, T-cell transduction with the 1928z CAR, biologic activity, quality control testing, and release criteria were met for all 4 validation runs using apheresis products from patients with CLL. Additionally, after expansion of the T cells, the diversity of the skewed Vbeta T-cell receptor repertoire was significantly restored. This validated process will be used in phase I clinical trials in patients with chemorefractory CLL and in patients with relapsed acute lymphoblastic leukemia. It can also be adapted for other clinical trials involving the expansion and transduction of patient or donor T cells using any CAR or T-cell receptor.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Scheme of the manufacturing process. The semi-closed system relies on the use of the Cytomate™ to wash the apheresis product prior to freezing and after thawing, the capture of CD3+CD28+ T cells with Dynabeads® and subsequent selection on the ClinExVivo magnetic particle concentrator (MPC), expansion in the Wave™ bioreactor, debeading on the ClinExVivo MPC and formulation using the Cytomate™.
FIGURE 2
FIGURE 2
T cell expansion, T cell concentration, glucose and lactate levels in the Wave Bioreactor during the course of VR1, VR2, VR3 and VR4. A, Total cumulative fold expansion of patient T cells. Data is shown from initial activation until completion of the expansion runs. B, Viable cell concentrations of patient T cells during activation and within the WAVE bioreactor. C, Glucose and D, Lactate levels were measured daily during the course of the validation runs.
FIGURE 3
FIGURE 3
In vitro and in vivo cytotoxic activity of the 1928z+ T cells. A, In vitro chromium release assays performed on 1928z+ EOP T cells derived from VR1, VR2, VR3 and VR4. Both autologous patient tumor B-CLL cells and Raji lymphoma cell line were used as target cells. B, Survival of mice bearing established disseminated Raji tumors after infusion of EOP 1928z+ T cells. Six days after intravenous injection of 5 × 105 Raji tumor cells, mice received 107 fresh 1928z CD3+ transduced T cells from VR4 run. Untransduced T cells from the same donor grown in parallel served as control. Note: we previously demonstrated that untransduced T cells and T cells transduced with an irrelevant CAR are equally unable to eradicate Raji tumors in vivo (data not shown).
FIGURE 4
FIGURE 4
Spectratyping analysis in T cells from the apheresis product and in the EOP 1928z T cells from VR1 and VR2. Representative spectratype analysis of Vβ1, Vβ3, Vβ9 and Vβ17 shows a skewed TCR repertoire in the T cells from the apheresis product and restored TCR repertoire in the EOP 1928z T cells after expansion with Dynabeads® (final product).
See this image and copyright information in PMC

References

    1. Johnson AJ, Mone AP, Abhyankar V, Byrd JC. Advances in the therapy of chronic lymphocytic leukemia. Curr Opin Hematol. 2003 Jul;10(4):297–305. - PubMed
    1. Frassoni F, Barrett AJ, Granena A, et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol. 1988 Nov;70(3):317–320. - PubMed
    1. Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol. 1991 Dec;79(4):567–574. - PubMed
    1. Michallet M, Tanguy ML, Socie G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM) Br J Haematol. 2000 Feb;108(2):400–407. - PubMed
    1. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 1;23(10):2346–2357. - PMC - PubMed

Publication types